Joint testing of mortality and a non-fatal outcome in clinical trials

被引:7
作者
McMahon, RP
Harrell, FE
机构
[1] Univ Maryland Baltimore Cty, Maryland Psychiat Res Ctr, Dept Psychiat, Baltimore, MD 21228 USA
[2] Univ Virginia, Sch Med, Dept Hlth Evaluat Sci, Div Biostat & Epidemiol, Charlottesville, VA 22908 USA
关键词
D O I
10.1002/sim.814
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
The following procedures are proposed for clinical trials of potentially lethal diseases with a nonfatal primary outcome: (i) comparison of treatments on worst-rank scores combining mortality and the non-fatal outcome; (ii) testing first for mortality differences, and then for differences on the worst-rank scoring if there is no significant evidence for mortality differences. Power and control of type I error rate while testing mortality and worst-rank scores by Bonferroni or closed testing procedures are compared. Used together these procedures improve power to detect treatments with favourable effects on both mortality and the designated non-fatal outcome, while reducing the likelihood of declaring that a treatment benefits patients when undetected adverse effects on mortality are present. Copyright (C) 2001 John Wiley & Sons, Ltd.
引用
收藏
页码:1165 / 1172
页数:8
相关论文
共 29 条
[1]   A TEST FOR THE DIFFERENCE BETWEEN 2 TREATMENTS IN A CONTINUOUS MEASURE OF OUTCOME WHEN THERE ARE DROPOUTS [J].
BROWN, MB .
CONTROLLED CLINICAL TRIALS, 1992, 13 (03) :213-225
[2]  
CONOVER WJ, 1980, PRACTICAL NONPARAMET, P217
[3]  
DEMETS DL, 1982, BIOMETRIKA, V69, P661
[4]  
Finkelstein DM, 1999, STAT MED, V18, P1341, DOI 10.1002/(SICI)1097-0258(19990615)18:11&lt
[5]  
1341::AID-SIM129&gt
[6]  
3.0.CO
[7]  
2-7
[8]   Carvedilol and the food and drug administration (FDA) approval process: The FDA paradigm and reflections on hypothesis testing [J].
Fisher, LD .
CONTROLLED CLINICAL TRIALS, 1999, 20 (01) :16-39
[9]   Surrogate end points in clinical trials: Are we being misled? [J].
Fleming, TR ;
DeMets, DL .
ANNALS OF INTERNAL MEDICINE, 1996, 125 (07) :605-613
[10]   A NEW APPROACH TO THE ANALYSIS OF CLINICAL DRUG TRIALS WITH WITHDRAWALS [J].
GOULD, AL .
BIOMETRICS, 1980, 36 (04) :721-727